These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17119258)

  • 1. Carcinogen exposure and epigenetic silencing in bladder cancer.
    Marsit CJ; Karagas MR; Schned A; Kelsey KT
    Ann N Y Acad Sci; 2006 Sep; 1076():810-21. PubMed ID: 17119258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinogen exposure and gene promoter hypermethylation in bladder cancer.
    Marsit CJ; Karagas MR; Danaee H; Liu M; Andrew A; Schned A; Nelson HH; Kelsey KT
    Carcinogenesis; 2006 Jan; 27(1):112-6. PubMed ID: 15987713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 alterations in bladder tumors from arsenic and tobacco exposed patients.
    Moore LE; Smith AH; Eng C; DeVries S; Kalman D; Bhargava V; Chew K; Ferreccio C; Rey OA; Hopenhayn C; Biggs ML; Bates MN; Waldman FM
    Carcinogenesis; 2003 Nov; 24(11):1785-91. PubMed ID: 12919957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer.
    Marsit CJ; Houseman EA; Schned AR; Karagas MR; Kelsey KT
    Carcinogenesis; 2007 Aug; 28(8):1745-51. PubMed ID: 17522068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between environmental tobacco smoke and arsenic methylation ability on the risk of bladder cancer.
    Chen YC; Su HJ; Guo YL; Houseman EA; Christiani DC
    Cancer Causes Control; 2005 Mar; 16(2):75-81. PubMed ID: 15868449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms?
    Simeonova PP; Luster MI
    J Environ Pathol Toxicol Oncol; 2000; 19(3):281-6. PubMed ID: 10983894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Environmental factors and genetic susceptibility promote urinary bladder cancer.
    Volanis D; Kadiyska T; Galanis A; Delakas D; Logotheti S; Zoumpourlis V
    Toxicol Lett; 2010 Mar; 193(2):131-7. PubMed ID: 20051252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis.
    Mink PJ; Alexander DD; Barraj LM; Kelsh MA; Tsuji JS
    Regul Toxicol Pharmacol; 2008 Dec; 52(3):299-310. PubMed ID: 18783726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic and bladder cancer: observations and suggestions.
    Radosavljević V; Jakovljević B
    J Environ Health; 2008 Oct; 71(3):40-2. PubMed ID: 18990932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radionuclides in cigarettes may lead to carcinogenesis via p16(INK4a) inactivation.
    Prueitt RL; Goodman JE; Valberg PA
    J Environ Radioact; 2009 Feb; 100(2):157-61. PubMed ID: 19070406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cigarette smoking and chromosome 9 alterations in bladder cancer.
    Zhang ZF; Shu XM; Cordon-Cardo C; Orlow I; Lu ML; Millon TV; Cao PQ; Connolly-Jenks C; Dalbagni G; Lianes P; Lacombe L; Reuter VE; Scher H
    Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):321-6. PubMed ID: 9149891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
    Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
    Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
    Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic biomarkers in urothelial bladder cancer.
    Kim WJ; Kim YJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of environmental and occupational cancer.
    Boffetta P
    Oncogene; 2004 Aug; 23(38):6392-403. PubMed ID: 15322513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
    Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-individual variability in toenail arsenic concentrations in a Michigan population, USA.
    Slotnick MJ; Meliker JR; Nriagu JO
    J Expo Sci Environ Epidemiol; 2008 Mar; 18(2):149-57. PubMed ID: 17426735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models for arsenic carcinogenesis: inorganic arsenic is a transplacental carcinogen in mice.
    Waalkes MP; Liu J; Ward JM; Diwan BA
    Toxicol Appl Pharmacol; 2004 Aug; 198(3):377-84. PubMed ID: 15276417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms in urinary bladder carcinogenesis.
    Volanis D; Papadopoulos G; Doumas K; Gkialas I; Delakas D
    J BUON; 2011; 16(4):589-601. PubMed ID: 22331708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.